Isarna gets $18M for antisense turnaround
By Cormac Sheridan
Tuesday, January 7, 2014
Isarna Therapeutics GmbH raised €13 million (US$17.7 million) in new investments and has secured access to a new chemistry platform to take a fresh stab a developing antisense inhibitors of transforming growth factor-beta (TGF-beta) in oncology indications.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.